Characterization of CR patients (n = 38) by transplant status and transplant type
| Characteristics . | CR patients who received SCT . | . | |
|---|---|---|---|
| Autologous (n = 8) . | Allogeneic (n = 8) . | No SCT (n = 22) . | |
| Median age in years (range) | 48.0 (17-61) | 46.0 (17-61) | 58.0 (14-76) |
| Female, n (%) | 5 (63) | 4 (50) | 8 (36) |
| ECOG performance status, n (%) | |||
| Grade 0 | 4 (50) | 2 (25) | 9 (41) |
| Grade 1 | 4 (50) | 6 (75) | 13 (59) |
| ALK status, n (%) | |||
| Positive | 1 (13) | 6 (75) | 3 (14) |
| Negative | 7 (88) | 2 (25) | 19 (86) |
| Disease status relative to most recent prior therapy, n (%)* | |||
| Relapsed | 3 (38) | 5 (63) | 14 (64) |
| Refractory | 5 (63) | 3 (38) | 8 (36) |
| Primary refractory disease, n (%)† | 5 (63) | 5 (63) | 13 (59) |
| Stage at initial diagnosis, n (%) | |||
| I/II | 5 (63) | 4 (50) | 8 (36) |
| III/IV | 2 (25) | 4 (50) | 10 (45) |
| Unknown | 1 (13) | 0 | 4 (18) |
| Median time in months from initial diagnosis to first dose (range) | 12.4 (5.2-32.4) | 23.9 (6.2-108.0) | 23.1 (4.4-186.5) |
| Median time in months from most recent relapse to first dose (range)‡ | 1.8 (0.8-2.8) | 1.2 (0.5-2.7) | 1.9 (0.4-2.9) |
| Baseline B symptoms, n (%)§ | 3 (38) | 5 (63) | 3 (14) |
| Fever | 2 (25) | 4 (50) | 0 |
| Night sweats | 2 (25) | 3 (38) | 3 (14) |
| Median baseline SPD of dominant nodes or nodal masses per investigator (cm2, range)|| | 11.5 (4.5-19.4) | 24.6 (11.7-76.8) | 10.7 (2.0-51.3) |
| Baseline bone marrow involvement, n (%) | 0 | 1 (13) | 1 (5) |
| Characteristics . | CR patients who received SCT . | . | |
|---|---|---|---|
| Autologous (n = 8) . | Allogeneic (n = 8) . | No SCT (n = 22) . | |
| Median age in years (range) | 48.0 (17-61) | 46.0 (17-61) | 58.0 (14-76) |
| Female, n (%) | 5 (63) | 4 (50) | 8 (36) |
| ECOG performance status, n (%) | |||
| Grade 0 | 4 (50) | 2 (25) | 9 (41) |
| Grade 1 | 4 (50) | 6 (75) | 13 (59) |
| ALK status, n (%) | |||
| Positive | 1 (13) | 6 (75) | 3 (14) |
| Negative | 7 (88) | 2 (25) | 19 (86) |
| Disease status relative to most recent prior therapy, n (%)* | |||
| Relapsed | 3 (38) | 5 (63) | 14 (64) |
| Refractory | 5 (63) | 3 (38) | 8 (36) |
| Primary refractory disease, n (%)† | 5 (63) | 5 (63) | 13 (59) |
| Stage at initial diagnosis, n (%) | |||
| I/II | 5 (63) | 4 (50) | 8 (36) |
| III/IV | 2 (25) | 4 (50) | 10 (45) |
| Unknown | 1 (13) | 0 | 4 (18) |
| Median time in months from initial diagnosis to first dose (range) | 12.4 (5.2-32.4) | 23.9 (6.2-108.0) | 23.1 (4.4-186.5) |
| Median time in months from most recent relapse to first dose (range)‡ | 1.8 (0.8-2.8) | 1.2 (0.5-2.7) | 1.9 (0.4-2.9) |
| Baseline B symptoms, n (%)§ | 3 (38) | 5 (63) | 3 (14) |
| Fever | 2 (25) | 4 (50) | 0 |
| Night sweats | 2 (25) | 3 (38) | 3 (14) |
| Median baseline SPD of dominant nodes or nodal masses per investigator (cm2, range)|| | 11.5 (4.5-19.4) | 24.6 (11.7-76.8) | 10.7 (2.0-51.3) |
| Baseline bone marrow involvement, n (%) | 0 | 1 (13) | 1 (5) |
SPD, sum of the products of diameters.
Relapse = best response of CR if a patient only had 1 prior therapy, or best response of CR or PR to most recent prior therapy if a patient had more than 1 prior therapy; refractory = best response of PR, stable disease (SD), or progressive disease (PD) if a patient had only 1 prior therapy, or best response of SD or PD to most recent prior therapy if a patient had more than 1 prior therapy.
No CR, or relapse within 3 months of frontline therapy.
For those with relapsed disease status to most recent prior therapy.
B symptoms present at the time of cycle 1, day 1.
SPD of up to 6 of the largest dominant nodes or nodal masses.